Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
traveler s diarrhea market insights epidemiology and market forecast

SALE

Traveler's Diarrhea - Market Insight, Epidemiology and Market Forecast - 2028

Published Date : 2019

Pages : 137

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
- Sample Request

traveler s diarrhea market insights epidemiology and market forecast

DelveInsight's 'Traveler's Diarrhea - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Traveler's Diarrhea (TD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted market size of Traveler's Diarrhea (CCA) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2017-2028

Traveler's Diarrhea (TD) - Disease Understanding

The DelveInsight’s Traveler's Diarrhea market report gives a thorough understanding of the Traveler's Diarrhea by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Traveler's Diarrhea Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Traveler's Diarrhea.

Traveler's Diarrhea Treatment

It covers the details of conventional and current medical therapies available in the Traveler's Diarrhea market for the treatment of the condition. It also provides Traveler's Diarrhea treatment algorithms and guidelines in the United States, Europe, and Japan.

Traveler's Diarrhea (TD) Epidemiology

The Traveler's Diarrhea (TD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Traveler's Diarrhea (TD) are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Traveler's Diarrhea (TD) Epidemiology Segmentation

The disease epidemiology covered in the report is segmented by total incident population, diagnosed population and severity-specific incident population of Traveler's Diarrhea.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the incident population of Traveler's Diarrhea (TD) was estimated to be 41,611,405 [7MM] in 2018. United States accounts for the highest TD cases (16,964,730 in 2018), followed by EU5 (Germany, France, Italy, Spain and UK) and Japan. Among the EU5 countries Germany had the highest incident patient population of Traveler's Diarrhea, followed by Italy.

Traveler's Diarrhea (TD) Drug Chapters

This segment of the Traveler's Diarrhea (TD) report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Traveler's Diarrhea (TD) Market Outlook

The Traveler's Diarrhea (TD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the global market of Traveler's Diarrhea (TD) was estimated to be USD 385.07 million in 2018. The United States accounts for the largest market size of Traveler's Diarrhea, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Currently, includes surgery with adjuvant chemotherapy and chemoradiation therapy. For the advanced and metastatic stage, systemic chemotherapy is the only option. There is no established second-line systemic therapy following progression after first-line treatment although chemotherapeutic agents either in monotherapy or in combination are used.

To meet the increasing demand for the treatment of Traveler's Diarrhea (TD), companies have shifted their focus towards the development of targeted therapies. Expected launch of potential targeted therapies including potential FGFR gene fusions and somatic mutations in IDH 1/2 in iCCA, PRKACA or PRKACB gene fusions in pCCA, and ELF3 mutations in dCCA/ampullary carcinoma, may increase the market size in the coming years, assisted by an increase in the incident population of Traveler's Diarrhea (TD) and awareness of the disease.

Traveler's Diarrhea (TD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Traveler's Diarrhea (TD) Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Traveler's Diarrhea (TD) Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition

Traveler's Diarrhea (TD) Report Assessment

• Current Treatment Practices

• Unmet Needs

• Detailed Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Traveler's Diarrhea (TD) market.

• Organize sales and marketing efforts by identifying the best opportunities for Traveler's Diarrhea (TD) market.

• To understand the future market competition in the Traveler's Diarrhea (TD) market.

1 Key Insights

2 Traveler's Diarrhea Market Overview at a Glance

2.1 Market Share (%) Distribution of Traveler's Diarrhea in 2017

2.2 Market Share (%) Distribution of Traveler's Diarrhea in 2028

3 Disease Background and Overview: Traveler's Diarrhea

3.1 Introduction

3.2 Causes

3.3 Consequences

3.4 Risk factors

3.5 Signs and Symptoms

3.6 Pathophysiology

3.7 Diagnosis

3.7.1 Conventional Diagnosis

3.7.2 Molecular Diagnostic Tools

3.7.3 History and Physical Examination

3.7.4 Diagnostic Testing

3.8 Diagnostic Algorithm

4 Epidemiology and Patient Population

4.1 Key Findings

4.2 7MM Total Incident Population of Traveler's Diarrhea

4.1 7MM Total Diagnosed Patient Population of Traveler's Diarrhea

5 Country Wise-Epidemiology of Traveler's Diarrhea

5.1 United States

5.1.1 Assumptions and Rationale

5.1.2 Total Incident Cases of Traveler's Diarrhea in the United States

5.1.3 Total Diagnosed Incident Cases of Traveler's Diarrhea in the United States

5.1.4 Severity-Specific Diagnosed Incident Cases of Traveler's Diarrhea in the United States

5.2 EU5 Countries

5.2.1 Assumptions and Rationale

5.3 Germany

5.3.1 Total Incident Cases of Traveler's Diarrhea in Germany

5.3.2 Total Diagnosed Incident Cases of Traveler's Diarrhea in Germany

5.3.3 Severity-Specific Diagnosed Incident Cases of Traveler's Diarrhea in Germany

5.4 France

5.4.1 Total Incident Cases of Traveler's Diarrhea in France

5.4.2 Total Diagnosed Incident Cases of Traveler's Diarrhea in France

5.4.3 Severity-Specific Diagnosed Incident Cases of Traveler's Diarrhea in France

5.5 Italy

5.5.1 Total Incident Cases of Traveler's Diarrhea in Italy

5.5.2 Total Diagnosed Incident Cases of Traveler's Diarrhea in Italy

5.5.3 Severity-Specific Diagnosed Incident Cases of Traveler's Diarrhea in Italy

5.6 Spain

5.6.1 Total Incident Cases of Traveler's Diarrhea in Spain

5.6.2 Total Diagnosed Incident Cases of Traveler's Diarrhea in Spain

5.6.3 Severity-Specific Diagnosed Incident Cases of Traveler's Diarrhea in Spain

5.7 United Kingdom

5.7.1 Total Incident Cases of Traveler's Diarrhea in the United Kingdom

5.7.2 Total Diagnosed Incident Cases of Traveler's Diarrhea in the United Kingdom

5.7.3 Severity-Specific Diagnosed Incident Cases of Traveler's Diarrhea in the United Kingdom

5.8 Japan

5.8.1 Assumptions and Rationale

5.8.1 Total Incident Cases of Traveler's Diarrhea in Japan

5.8.2 Total Diagnosed Incident Cases of Traveler's Diarrhea in Japan

5.8.3 Severity-Specific Diagnosed Incident Cases of Traveler's Diarrhea in Japan

6 Treatment

6.1 Oral Hydration and diet

6.2 Anti-motility Agents

6.3 Antibiotics

6.4 Treatment of TD Caused by Protozoa

6.5 Treatment on the basis of severity

6.6 Treatment for Children

6.7 United States Guidelines on Traveler's Diarrhea

7 Unmet Needs

8 Marketed Drugs

8.1 Aemcolo/Relafalk: Cosmo Pharmaceuticals

8.1.1 Drug Description

8.1.2 Regulatory Milestones

8.1.3 Other Development Activities

8.1.4 Safety and Efficacy

8.1.5 Product Profile

8.2 Xifaxan: Salix Pharmaceuticals

8.2.1 Drug Description

8.2.2 Regulatory Milestones

8.2.3 Other Development Activities

8.2.4 Safety and Efficacy

8.2.5 Product Profile

9 Emerging Drugs

9.1 Key Cross Competition

9.2 Etvax: Scandinavian Biopharma

9.2.1 Product Description

9.2.2 Other Development Activities

9.2.3 Clinical Development

9.2.4 Product Profile

9.3 Bismuth Subsalicylate: Procter and Gamble

9.3.1 Product Description

9.3.2 Other Development Activities

9.3.3 Clinical Development

9.3.4 Product Profile

10 Traveler's Diarrhea: 7 Major Market Analysis

10.1 Key Findings

10.2 Market Size of Traveler's Diarrhea in 7MM

11 The United States Market Outlook

11.1 United States Market Size

11.1.1 Total Market size of Traveler's Diarrhea

11.1.2 Market Size by Therapies

12 EU-5 Countries: Market Outlook

12.1 Germany

12.1.1 Total Market size of Traveler's Diarrhea in Germany

12.1.2 Market Size by Emerging Therapies

12.2 France

12.2.1 Total Market Size of Traveler's Diarrhea

12.2.2 Market Size by Emerging Therapies

12.3 Italy

12.3.1 Total Market Size of Traveler's Diarrhea

12.3.2 Market Size by Emerging Therapies

12.4 Spain

12.4.1 Total Market Size of Traveler's Diarrhea

12.4.2 Market Size by Emerging Therapies

12.5 United Kingdom

12.5.1 Total Market Size of Traveler's Diarrhea

12.5.2 Market Size by Emerging Therapies

13 Japan: Market Outlook

13.1 Japan market Size

13.1.1 Total Market Size of Traveler's Diarrhea

13.1.2 Market Size by Emerging Therapies

14 Market Drivers

15 Market Barriers

16 Appendix

16.1 Report Methodology

17 DelveInsight Capabilities

18 Disclaimer

19 About DelveInsight

List of Tables:

Table 1: Causes of Traveler's Diarrhea

Table 2: Risk factors for traveler's diarrhea

Table 3: Enteric Disease Clinical Syndromes

Table 4: Clinical presentation of diarrhea acquired during International Travel to Developing Countries

Table 5: Pathogenic Mechanisms in travelers' diarrhea by aetiology

Table 6: Main advantages and disadvantages of using different methods to diagnose traveller's diarrhea

Table 7: Inflammatory and Non-inflammatory factors responsible for TD

Table 8: Causative agents responsible for Symptoms associated with Traveler's Diarrhoea

Table 9: Associated Potential Pathogens and their related Historical Counterparts

Table 10: Total Incident Population of Traveler's Diarrhea in the 7MM (2017-2028)

Table 11: Total Diagnosed Population of Traveler's Diarrhea in the 7MM (2017-2028)

Table 12: Total Incident Cases of Traveler's Diarrhea in the United States (2017-2028)

Table 13: Total Diagnosed Incident Cases of Traveler's Diarrhea in the United States (2017-2028)

Table 14: Severity-Specific Diagnosed Incident Cases of Traveler's Diarrhea in the United States (2017-2028)

Table 15: Total Incident Cases of Traveler's Diarrhea in Germany (2017-2028)

Table 16: Total Diagnosed Incident Cases of Traveler's Diarrhea in Germany (2017-2028)

Table 17: Severity Specific Diagnosed Incident Cases of Traveler's Diarrhea in Germany (2017-2028)

Table 18: Total Incident Cases of Traveler's Diarrhea in France (2017-2028)

Table 19: Total Diagnosed Incident Cases of Traveler's Diarrhea in France (2017-2028)

Table 20: Severity Specific Diagnosed Incident Cases of Traveler's Diarrhea in France (2017-2028)

Table 21: Total Incident Cases of Traveler's Diarrhea in Italy (2017-2028)

Table 22: Total Diagnosed Incident Cases of Traveler's Diarrhea in Italy (2017-2028)

Table 23: Severity Specific Diagnosed Incident Cases of Traveler's Diarrhea in Italy (2017-2028)

Table 24: Total Incident Cases of Traveler's Diarrhea in Spain (2017-2028)

Table 25: Total Diagnosed Incident Cases of Traveler's Diarrhea in Spain (2017-2028)

Table 26: Severity-Specific Diagnosed Incident Cases of Traveler's Diarrhea in Spain (2017-2028)

Table 27: Total Incident Cases of Traveler's Diarrhea in the United Kingdom (2017-2028)

Table 28: Total Diagnosed Incident Cases of Traveler's Diarrhea in the United Kingdom (2017-2028)

Table 29: Severity-Specific Diagnosed Incident Cases of Traveler's Diarrhea in the United Kingdom (2017-2028)

Table 30: Total Incident Cases of Traveler's Diarrhea in Japan (2017-2028)

Table 31: Total Diagnosed Incident Cases of Traveler's Diarrhea in Japan (2017-2028)

Table 32: Severity-Specific Diagnosed Incident Cases of Traveler's Diarrhea in Japan (2017-2028)

Table 33: Comparison of emerging drugs under development

Table 34: Clinical Trial Description

Table 35: Clinical Trial Description

Table 36: 7 Major Market Size of Traveler's Diarrhea in USD Million (2017-2028)

Table 37: United States Market Size of Traveler's Diarrhea in US, USD Million (2017-2028)

Table 38: Market size of Traveler's Diarrhea by therapies in United States, in USD Million (2017-2028)

Table 39: Market Size of Traveler's Diarrhea in Germany, in USD Million (2017-2028)

Table 40: Market size of Traveler's Diarrhea by therapies in Germany, in USD Million (2017-2028)

Table 41: Market Size of Traveler's Diarrhea in France, in USD Million (2017-2028)

Table 42: Market size of Traveler's Diarrhea by therapies in France, in USD Million (2017-2028)

Table 43: Market Size of Traveler's Diarrhea in Italy, in USD Million (2017-2028)

Table 44: Market size of Traveler's Diarrhea by therapies in Italy, in USD Million (2017-2028)

Table 45: Market Size of Traveler's Diarrhea in Spain, in USD Million (2017-2028)

Table 46: Market size of Traveler's Diarrhea by therapies in Spain, in USD Million (2017-2028)

Table 47: Market Size of Traveler's Diarrhea in the UK, in USD Million (2017-2028)

Table 48: Market size of Traveler's Diarrhea by therapies in the UK, in USD Million (2017-2028)

Table 49: Market Size of Traveler's Diarrhea in Japan, in USD Million (2017-2028)

Table 50: Market size of Traveler's Diarrhea by therapies in Japan, in USD Million (2017-2028)

List of Figures:

Figure 1: Signs and Symptoms of Travelers' diarrhea

Figure 2: Normal intestinal physiology and alteration by pathogens and their toxins.

Figure 3: Diagnostic Algorithm for deciding when testing is required in patients who present with Infectious diarrhea

Figure 4: Total Incident Population of Traveler's Diarrhea in the 7MM (2017-2028)

Figure 5: Total Diagnosed Patient Population of Traveler's Diarrhea in the 7MM (2017-2028)

Figure 6: Total Incident Cases of Traveler's Diarrhea in the United States (2017-2028)

Figure 7: Total Diagnosed Incident Cases of Traveler's Diarrhea in the United States (2017-2028)

Figure 8: Severity-Specific Diagnosed Incident Cases of Traveler's Diarrhea in the United States (2017-2028)

Figure 9: Total Incident Cases of Traveler's Diarrhea in Germany (2017-2028)

Figure 10: Total Diagnosed Incident Cases of Traveler's Diarrhea in Germany (2017-2028)

Figure 11: Severity Specific Diagnosed Incident Cases of Traveler's Diarrhea in Germany (2017-2028)

Figure 12: Total Incident Cases of Traveler's Diarrhea in France (2017-2028)

Figure 13: Total Diagnosed Incident Cases of Traveler's Diarrhea in France (2017-2028)

Figure 14: Age- Specific Diagnosed Incidence Cases of Traveler's Diarrhea in France (2017-2028)

Figure 15: Total Incident Cases of Traveler's Diarrhea in Italy (2017-2028)

Figure 16: Total Diagnosed Incident Cases of Traveler's Diarrhea in Italy (2017-2028)

Figure 17: Severity-Specific Diagnosed Incident Cases of Traveler's Diarrhea in Italy (2017-2028)

Figure 18: Total Incident Cases of Traveler's Diarrhea in Spain (2017-2028)

Figure 19: Total Diagnosed Incident Cases of Traveler's Diarrhea in Spain (2017-2028)

Figure 20: Severity-Specific Diagnosed Incident Cases of Traveler's Diarrhea in Spain (2017-2028)

Figure 21: Total Incident Cases of Traveler's Diarrhea in the United Kingdom (2017-2028)

Figure 22: Total Diagnosed Incident Cases of Traveler's Diarrhea in the United Kingdom (2017-2028)

Figure 23: Severity-Specific Diagnosed Incident Cases of Traveler's Diarrhea in the United Kingdom (2017-2028)

Figure 24: Total Incident Cases of Traveler's Diarrhea in Japan (2017-2028)

Figure 25: Total Diagnosed Incident Cases of Traveler's Diarrhea in Japan (2017-2028)

Figure 26: Severity-Specific Diagnosed Incident Cases of Traveler's Diarrhea in Japan 2017-2028)

Figure 27: Algorithmic approach to the treatment of traveler's diarrhea.

Figure 28:Traveler's Diarrhea (TD) Flow Chart for Drug Treatment for Adults

Figure 29: Unmet Needs of Traveler's Diarrhea

Figure 30: 7 Major Market Size of Traveler's Diarrhea in USD Million (2017-2028)

Figure 31: Market Size of Traveler's Diarrhea in the United States, USD Millions (2017-2028)

Figure 32: Market size of Traveler's Diarrhea by therapies in the US, in USD Million (2017-2028)

Figure 33: Market Size of Traveler's Diarrhea in Germany, USD Million (2017-2028)

Figure 34: Market Size of Traveler's Diarrhea by therapies, in Germany, in USD Million (2017-2028)

Figure 35: Market Size of Traveler's Diarrhea in France, USD Million (2017-2028)

Figure 36: Market Size of Traveler's Diarrhea by therapies, in France, in USD Million (2017-2028)

Figure 37: Market Size of Traveler's Diarrhea in Italy, USD Million (2017-2028)

Figure 38: Market Size of Traveler's Diarrhea by therapies in Italy, in USD Million (2017-2028)

Figure 39: Market Size of Traveler's Diarrhea in Spain, USD Million (2017-2028)

Figure 40: Market Size of Traveler's Diarrhea by therapies in Spain, in USD Million (2017-2028)

Figure 41: Market Size of Traveler's Diarrhea in the UK, USD Million (2017-2028)

Figure 42: Market Size of Traveler's Diarrhea by therapies in the UK, in USD Million (2017-2028)

Figure 43: Market Size of Traveler's Diarrhea in Japan, USD Million (2017-2028)

Figure 44: Market Size of Traveler's Diarrhea by therapies in Japan, in USD Million (2017-2028)

Figure 45: Market Drivers

Figure 46: Market Barriers

Tags:

License Type

Offer